|
Technology: Altered Energy Metabolism Directed (AEMD) Platform |
Our AEMD small molecule drug platform exploits biochemical alterations in the conversion of glucose to energy that occurs in many types of cancer cells. Our Thioctan class of AEMD drugs has been shown to perturb the activity of key metabolic and regulatory processes involved in cancer energy production. These perturbations lead to cell death in a wide spectrum of human tumor cell types, including those that are resistant to traditional chemotherapeutic agents.
Our lead Thioctan drug candidate, CPI-613 and related molecules, have minimal toxic effects on normal cells in culture at exposure levels that induce death cancer cells in culture. These compounds are well tolerated in animal models at doses that significantly exceed therapeutically beneficial doses. This attractive combination of features warrants the further evaluation of Thioctans in human clinical studies.
|
